AllSight
BLFS · ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS · 8-K · Item 2.02 · Aug 6, 2026

Revenue edged past consensus as underlying profitability improved, but margins slipped

BIOLIFE SOLUTIONS INC (BLFS) — AllSight decodes this SEC 8-K in plain English, versus what the market expected.
MetricQ2 2026Q2 2025Market expectation / reference
Revenue$28.5M$23.4M~$27.8M consensus
GAAP diluted EPS$0.91$(0.32)~$0.03 consensus
Adjusted net income$4.2M$0.6M—
Adjusted EBITDA$7.4M$5.6M26% margin vs. 24%
GAAP gross margin64%65%—
Adjusted gross margin65%66%—
Read the original 8-K on SEC EDGAR ↗
Open live on AllSight — the whole market, decoded →
AllSight turns SEC filings into plain-English, neutral reads and objective market context. We explain what happened and how it lands versus expectations — we do not give investment advice or predict prices. Decoded straight from the filing; check it against the source.